Reference:	FOI.18127.25
Subject:	Blueteq prior-approvals for Bevacizumab Gamma
Date of Request:	19 August 2025

Requested:

Under the Freedom of Information Act 2000, please provide the following recorded information held by your Integrated Care Board regarding use of bevacizumab gamma (Lytenava®) for neovascular (wet) age-related macular degeneration (NICE TA1022):

Scope & period

- 1 June 2025 – 30 June 2025
- 1 July 2025 – 31 July 2025

1. Information requested (for each month above):

   a. Total number of Blueteq prior-approval forms submitted for bevacizumab gamma (Lytenava) for wet AMD within your ICB.

Please split totals into:

   b. Initiation forms (treatment starts)

   c. Continuation forms (ongoing approvals / renewals)

If held, please also provide a breakdown by provider Trust within your ICB.

Response:

Integrated Care Boards (ICBs) are a feature of the NHS in England. Hywel Dda University Health Board (UHB) is part of NHS Wales and is an integrated Local Health Board responsible for the planning and provision of primary, community and in hospital services, based on the needs of the local community across three (3) counties. Therefore, the information relating to the UHB is provided below.

1a. The UHB confirm zero (0) Blueteq prior-approval forms for Bevacizumab Gamma (Lytenava) for wet age-related macular degeneration (AMD), were submitted during the periods 1 to 30 June and 1 to 31 July 2025. Additionally, the UHB can confirm Blueteq has not yet been activated within its Ophthalmology departments.

1b. & 1c. Not applicable.